Desidustat in anaemia in patients with chronic kidney disease: a profile of its use
Declarations
Funding The preparation of this review was not supported by any external funding.
Authorship and conflict of interest Tina Nie and Yahiya Syed are salaried employees of Adis International Ltd/Springer Nature and declare no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.
Ethics approval, Consent to participate, Consent for publication, Availability of data and material, Code availability Not applicable.
Additional information about this Adis Drug Review can be found here.
Abstract
Desidustat (Oxemia™), a hypoxia-inducible factor prolyl hydroxylase inhibitor, is a promising new oral alternative to injectable erythropoiesis-stimulating agents (ESAs) for the treatment of anaemia in patients with chronic kidney disease (CKD). Desidustat is approved in India for adults with CKD who are either not on dialysis or on dialysis. It is administered orally three times a week and dosage should be individualised based on the haemoglobin response of the patient. In clinical trials in patients with non-dialysis-dependent and dialysis-dependent CKD, desidustat was non-inferior to darbepoetin alfa and epoetin alfa, respectively, in increasing haemoglobin levels. Desidustat was generally well tolerated in clinical trials of up to 24 weeks and had a broadly similar tolerability and safety profile to darbepoetin alfa and epoetin alfa. The most common adverse events with desidustat were peripheral oedema in patients with non-dialysis-dependent CKD, and pyrexia, increased blood potassium, nausea and chills in patients with dialysis-dependent CKD.
© Springer Nature Switzerland AG 2023
